Investor Relations
Investing in Johnson & Johnson
Johnson & Johnson has been a part of people's lives for more than 120 years and a valuable part of their investments for more than 60 years. Founded in 1886, we listed our shares on the New York Stock Exchange for public investors in 1944.
During our history, we have built the most comprehensive base of health care businesses in the world, generating more than 70 percent of our revenues from No. 1 or No. 2 global leadership positions in our respective markets.
Our consistent performance has enabled us to deliver an exceptional track record of growth that few, if any, companies can claim: 76 consecutive years of sales increases; 25 consecutive years of adjusted earnings increases; and 47 consecutive years of dividend increases. Over the last 10 years, Johnson & Johnson stock generated a 5.6 percent total return for investors compared to a
Our consumer products, pharmaceuticals, medical devices and diagnostics play a role in helping millions of people be well and stay well every day. We remain committed to improving the health and well-being of people everywhere, profitably growing our businesses, and enhancing the value we can bring to our shareholders.
2008 Annual Report
The financial success of Johnson & Johnson depends on ensuring that our customers, our employees, the communities in which we operate and the environment on which we depend thrive with us. As a way to be more environmentally responsible, we offer the option of viewing future Annual Reports and Proxy Statements on the Internet. Johnson & Johnson registered shareholders can sign up to receive these materials via e-mail instead of having paper copies sent through the mail. Our Annual Report and Proxy Statement can be accessed on-line at your convenience and easily printed from your computer. To register for this service, please go to www.computershare.com/jnj/ecomms or contact our transfer agent, Computershare, at 1-800-328-9033.
Please note, if you own your stock through a broker or bank, you will need to contact your broker or bank to process your request for electronic delivery of the Annual Report and Proxy Statement.
Investor News
July 3, 2009
Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology
July 2, 2009
Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment
June 29, 2009
Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories
Investor Communications
July 14, 2009 at 8:30 AM ET
Johnson & Johnson Second Quarter 2009 Earnings Conference Call
Financial Quick Links
Q1 2009 Earnings Announcement
Q1 2009 Sales of Key Products/Franchises
Investor Facts
5 Year Financial Review
1. Data source - Bloomberg
